Relatively decreased expression in the bone marrow of subjects with chronic myeloid leukemia (CML) compared with nonleukemic subjects suggests that Irf8 functions as a leukemia suppressor (13). Here, IRF8 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.